Long‐Term Results of GnRH Analogue (Buserelin) Treatment in Girls with Central Precocious Puberty

Abstract
The GnRH analogue Buserelin was given for one year to six girls with central precocious puberty in a daily subcutaneous dose of 20 .mu.g/kg/day. A decrease of plasma estradiol and vaginal maturation index to prepubertal values was obtained in 5 out of 6 cases. Bone maturation decreased and final predicted adult height improved significantly. This analogue of GnRH appears to be an effective medication for gonadotropin dependent precocious puberty in girls.

This publication has 9 references indexed in Scilit: